---
title: Improving NSCLC Treatment Outcomes | Adjuvant Genomics
description: Adjuvant Genomics provides cutting-edge genomic insights for NSCLC patients, empowering oncologists with a risk and treatment response score.
image: https://adjuvantgx.com/hubfs/featured%20image.png
---

[Skip to content](https://adjuvantgx.com#main-content)

![Logo 1000004414](https://adjuvantgx.com/hubfs/Logo%201000004414.svg)

Open main navigation

Close main navigation

**Welcome**

# We are Adjuvant Genomics

We aim to help improve the prognosis and treatment outcomes for patients with Stage 1 & 2  non-small cell lung (NSCLC) cancer.

## Patients face uncertainty about cancer recurrence risk and the effectiveness of adjuvant chemotherapy vs. immunotherapy.

Despite curative resection, 30-55% of NSCLC patients experience recurrence and die1. Patients face uncertainty about cancer recurrence risk and the effectiveness of adjuvant chemotherapy vs. immunotherapy.

1. 10.1200/CCI.22.00062 JCO Clinical Cancer Informatics no. 7 (2023) e2200062. Published online July 10, 2023.

![Frame 484](https://adjuvantgx.com/hubfs/Frame%20484.png "Frame 484")

**Our Solution**

## Expanding horizons in non-small cell lung cancer care

- We identify high-risk patients who are more likely to experience cancer recurrence.
- We predict a patient’s responsiveness to adjuvant chemotherapy, streamlining treatment selection.
- We support a faster transition to alternative adjuvant therapies for those unlikely to benefit from adjuvant chemotherapy.

**THE SCIENCe**

## The assay's efficacy is supported by comprehensive clinical research

We believe our assay identifies high risk of recurrence and who will benefit from chemotherapy, minimizing unnecessary treatments. Based on validation studies, we also believe the assay and test predicts patient outcomes with a high degree of certainty, paving the way for personalized medicine in lung cancer.

![Stocksy_txp9db27673udw200_Large_2772906](https://adjuvantgx.com/hubfs/raw_assets/public/@marketplace/Drive_Web_Studio/Accelerator/images/img-girl.jpg "Stocksy_txp9db27673udw200_Large_2772906")

> ## "We embarked on this journey with a clear vision: to transform the landscape of lung cancer care..."
> 
> 
> 
> ![Frame 1000004413](https://adjuvantgx.com/hubfs/Frame%201000004413.png)
> 
> Robert Jacoby
> 
> Chief Business Officer, Adjuvant Genomics Inc.

### Let's Connect

# Adjuvant Genomics, Inc.

![Mono Dark 1000004420](https://adjuvantgx.com/hubfs/Mono%20Dark%201000004420.svg)

We aim to help improve the prognosis and treatment outcomes for patients with Stage 1 & 2  non-small cell lung cancer.

facebook-f icon linkedin-in icon twitter icon instagram icon

**Pages**

[Home](https://adjuvantgx.com/?hsLang=en)

[Privacy Policy](https://adjuvantgx.com/privacy-policy?hsLang=en)

[Terms of Use](https://adjuvantgx.com/terms-conditions?hsLang=en)

**Connect**

[LinkedIn](https://www.linkedin.com/company/adjuvant-genomics-inc)

[Twitter](https://twitter.com/AdjuvantGX)

© 2026 Adjuvant Genomics, Inc. All rights reserved.